155 related articles for article (PubMed ID: 37085152)
1. Randomized clinical Trial Comparing drug Eluting Stent Zilver PTX® Versus Bare Metal Stent Zilver Flex® for Treatment of Lesions in Femoral and Popliteal Arteries in Chronic Limb Threatening Ischemia.
Fransson T; Gottsäter A; Abdulrasak M; Malina M; Resch T
Vasc Endovascular Surg; 2023 Oct; 57(7):706-716. PubMed ID: 37085152
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial.
Gouëffic Y; Torsello G; Zeller T; Esposito G; Vermassen F; Hausegger KA; Tepe G; Thieme M; Gschwandtner M; Kahlberg A; Schindewolf M; Sapoval M; Diaz-Cartelle J; Stavroulakis K;
Circulation; 2022 Nov; 146(21):1564-1576. PubMed ID: 36254728
[TBL] [Abstract][Full Text] [Related]
3. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Machan LS; Snyder SA; O'Leary EE; Ragheb AO; Zeller T;
Circulation; 2016 Apr; 133(15):1472-83; discussion 1483. PubMed ID: 26969758
[TBL] [Abstract][Full Text] [Related]
4. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
Tran K; Ullery BW; Kret MR; Lee JT
Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
[TBL] [Abstract][Full Text] [Related]
5. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies.
Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Snyder SA; O'Leary EE; Tepe G; Scheinert D; Zeller T;
J Am Coll Cardiol; 2013 Jun; 61(24):2417-2427. PubMed ID: 23583245
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness Study of Drug-Eluting and Bare-Metal Peripheral Artery Stents in Endovascular Femoropopliteal Artery Revascularization.
Jeon-Slaughter H; Khalili H; Tsai S; Armstrong EJ; Shammas NW; Jawaid O; Lu H; Addo T; Gigliotti O; Abu-Fadel M; Banerjee S
J Invasive Cardiol; 2018 Oct; 30(10):373-379. PubMed ID: 30279293
[TBL] [Abstract][Full Text] [Related]
7. A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
Gouëffic Y; Sauguet A; Desgranges P; Feugier P; Rosset E; Ducasse E; Kaladji A; Salomon du Mont L; Pernès JM; Commeau P; Lermusiaux P; Leclere B; Guyomarc'h B; Hoffmann CT; Maurel B
JACC Cardiovasc Interv; 2020 Feb; 13(4):447-457. PubMed ID: 32081238
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcome of Drug-Eluted Stenting (Zilver PTX) in Patients With Femoropopliteal Occlusive Disease a Single Center Experience.
AbuRahma AF; Beasley M; AbuRahma ZT; Davis M; Adams E; Dean LS; Shapiro J; Scott G; Davis E
J Endovasc Ther; 2022 Jun; 29(3):350-360. PubMed ID: 34622706
[TBL] [Abstract][Full Text] [Related]
9. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.
Gray WA; Keirse K; Soga Y; Benko A; Babaev A; Yokoi Y; Schroeder H; Prem JT; Holden A; Popma J; Jaff MR; Diaz-Cartelle J; Müller-Hülsbeck S;
Lancet; 2018 Oct; 392(10157):1541-1551. PubMed ID: 30262332
[TBL] [Abstract][Full Text] [Related]
10. Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 12-Month Results.
Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
JACC Cardiovasc Interv; 2016 Feb; 9(3):271-277. PubMed ID: 26847118
[TBL] [Abstract][Full Text] [Related]
11. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery).
Liistro F; Grotti S; Porto I; Angioli P; Ricci L; Ducci K; Falsini G; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
JACC Cardiovasc Interv; 2013 Dec; 6(12):1295-302. PubMed ID: 24239203
[TBL] [Abstract][Full Text] [Related]
12. Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results.
Kichikawa K; Ichihashi S; Yokoi H; Ohki T; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
Cardiovasc Intervent Radiol; 2019 Mar; 42(3):358-364. PubMed ID: 30411151
[TBL] [Abstract][Full Text] [Related]
13. Efficacy analysis following polymer coated drug eluting stent and bare metal stent deployment for femoropopliteal arterial disease.
Shehada Y; Bisdas T; Argyriou A; Torsello G; Tsilimparis N; Beropoulis E; Stavroulakis K
Vascular; 2024 Feb; 32(1):102-109. PubMed ID: 36070428
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of the paclitaxel-eluting Eluvia stent for long femoropopliteal lesions in Asian patients with predominantly chronic limb-threatening ischemia.
Kum S; Ipema J; Huizing E; Tan YK; Lim D; Lok IY; Hazenberg CE; Ünlü Ç
Vasc Med; 2021 Jun; 26(3):267-272. PubMed ID: 33733963
[TBL] [Abstract][Full Text] [Related]
15. Penetration rate of the placement of a drug-eluting stent for the treatment of superficial femoral artery lesions in Japan.
Mori S; Hirano K; Yamauchi Y; Hayashi E; Doijiri T; Takamura T; Maeda A; Okuda J; Mizuno K; Onishi Y; Iwaki T; Tsukahara K; Shinozaki N; Araki H; Kongoji K; Sugano T; Miyamoto A; Michishita I
Heart Vessels; 2017 Sep; 32(9):1093-1098. PubMed ID: 28451834
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results.
Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Zeller T; Roubin GS; Burket MW; Khatib Y; Snyder SA; Ragheb AO; White JK; Machan LS;
Circ Cardiovasc Interv; 2011 Oct; 4(5):495-504. PubMed ID: 21953370
[TBL] [Abstract][Full Text] [Related]
17. ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions.
Bosiers M; Setacci C; De Donato G; Torsello G; Silveira PG; Deloose K; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Callaert J; Eckstein HH; Teβarek J; Giaquinta A; Wauters J
J Endovasc Ther; 2020 Apr; 27(2):287-295. PubMed ID: 31997715
[No Abstract] [Full Text] [Related]
18. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).
Lammer J; Zeller T; Hausegger KA; Schaefer PJ; Gschwendtner M; Mueller-Huelsbeck S; Rand T; Funovics M; Wolf F; Rastan A; Gschwandtner M; Puchner S; Ristl R; Schoder M
J Am Coll Cardiol; 2013 Oct; 62(15):1320-7. PubMed ID: 23831445
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions.
Tsujimura T; Takahara M; Iida O; Soga Y; Katsuki T; Fujihara M; Kawasaki D; Kozuki A; Mano T
J Vasc Surg; 2021 Jun; 73(6):1998-2008.e1. PubMed ID: 33347998
[TBL] [Abstract][Full Text] [Related]
20. Real-world outcomes of Cook Zilver PTX in femoro-popliteal district from multicenter experience.
Bianchini Massoni C; Strozzi F; Epifani E; Zenunaj G; Ucci A; Paladini I; Gasbarro V; Tusini N; Freyrie A
Int Angiol; 2023 Feb; 42(1):9-18. PubMed ID: 36534022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
